Everest Medicines Ltd banner
E

Everest Medicines Ltd
HKEX:1952

Watchlist Manager
Everest Medicines Ltd
HKEX:1952
Watchlist
Price: 33.02 HKD -4.01% Market Closed
Market Cap: HK$11.7B

Intrinsic Value

The intrinsic value of one Everest Medicines Ltd stock under the Base Case scenario is 41.7 HKD. Compared to the current market price of 33.02 HKD, Everest Medicines Ltd is Undervalued by 21%.

Intrinsic Value
41.7 HKD
Undervaluation 21%
Intrinsic Value
Price
E
Worst Case
Base Case
Best Case
Get notified when the price drop
Track Buy Zone
20% below Intrinsic Value HK$33.36
Get notified when the price drops into your buy zone
Intrinsic Value HK$41.7
Margin of Safety 20% HK$33.36
Current Price HK$33.02
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Valuation History
Ask AI Assistant
What other research platforms think about Everest Medicines Ltd?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is Everest Medicines Ltd valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Everest Medicines Ltd.

Explain Valuation
Alternatives to Everest Medicines Ltd

Fundamental Analysis

Financials
Efficiency

Earnings Waterfall
Everest Medicines Ltd

Wall St
Price Targets

Dividends

Everest Medicines Ltd
does not pay dividends
Shareholder Yield

Competitive Landscape

What is the Intrinsic Value of one Everest Medicines Ltd stock?

The intrinsic value of one Everest Medicines Ltd stock under the Base Case scenario is 41.7 HKD.

Is Everest Medicines Ltd stock undervalued or overvalued?

Compared to the current market price of 33.02 HKD, Everest Medicines Ltd is Undervalued by 21%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett